STUDY OF THE JAK INHIBITOR RUXOLITINIB ADMINISTERED ORALLY TO PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA-MYELOFIBROSIS (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA-MYELOFIBROSIS (PET-MF):